Immunome Director Jean Jacques Bienaime purchased 6,000 shares for $116,880, marking the largest purchase of his career. This bullish signal arrives as the stock trades down 32.69% from its 52-week high and nears a key FDA decision for its varegacestat program.
Price context
IMNM is down 3.67% over the last five days and 17.07% over the past month, currently trading at $18.61. The stock remains 32.69% below its 52-week high of $27.65 despite a strong 100.76% gain over the last year.
Catalysts to watch
- •FDA NDA filing for varegacestat in May 2026 (Source: News 2026-05-12)
- •Oral presentation of varegacestat data at the 2026 ASCO Annual Meeting (Source: News 2026-05-11)
- •Largest ever insider purchase by Jean Jacques Bienaime on June 5, 2026 (Source: Signal flags)
Risks
- •High beta of 2.07 indicates significant volatility.
- •Short interest covers 18.21% of the float.
AI-generated context from public data. Not investment advice. Verify before trading.